JPMorgan analyst Tessa Romero kept a Neutral rating with no price target on Prime Medicine (PRME) following a transfer of coverage. The firm says it would consider recommending the shares as the company moves closer to “value-creating milestones.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRME:
- Cautious Hold Rating for Prime Medicine, Inc. Amid Promising Preclinical Results and Extended Development Timeline
- Prime Medicine’s Promising Advances in Gene Editing Justify Buy Rating
- Prime Medicine price target lowered to $4.25 from $5 at Citi
- Prime Medicine Advances Genetic Therapy Pipeline in Q3 2025
- Prime Medicine files automatic mixed securities shelf